secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ovid Therapeutics Inc. (OVID)
CIK:        0001636651
Form:       8-K
Filed at:   2024-06-07T23:59:59+00:00
Accession:  0000950170-24-070673
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Ovid Therapeutics stockholders elect directors, approve executive compensation, ratify KPMG
--------------------------------------------------------------------------------

- Proposal 1: Barbara Duncan and Robert Michael Poole elected to board; For votes 36.7M and 40.2M respectively.
- Proposal 2: Advisory vote on executive compensation approved with 40.5M For, 1.76M Against, 0.01M Abstain.
- Proposal 3: Ratification of KPMG as auditor for FY2024 passed with 57.2M For, 1.29M Against, 9,375 Abstain.
- Broker non-votes totaled 16.2M shares on Proposals 1 and 2.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636651/000095017024070673/0000950170-24-070673-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636651/000095017024070673/ovid-20240607.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-070673

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer